Biomarkers and response to bevacizumab-letter

Clinical Cancer Research

Volumn 20, Issue 4, 2014, Pages 1056-1057

  Cremolini, Chiara ^a   Loupakis, Fotios ^a   Bocci, Guido ^b,d   Falcone, Alfredo ^a,c,d  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b Department of Clinical and Experimental Medicine ^*  (United Kingdom)

^c UNIVERSITY OF PISA   (Italy)

^d ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

BREAST CANCER; DRUG INDICATION; HER 2 NEGATIVE METASTATIC BREAST CANCER; HUMAN; LETTER; METASTATIC COLORECTAL CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; TRIPLE NEGATIVE BREAST CANCER;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PATIENT SELECTION; PERITONEAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896717371     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2763     Document Type: Letter

References (7)

1. Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res 2013;19:5227-39.
2. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
3. Masi G, Loupakis F, Salvatore L, Cremolini C, Fornaro L, Schirripa M, et al. A randomized phase III study evaluating the continuation of Bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 23, 2012 (suppl 9; abstr LBA17).
4. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L Masi G, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011;104: 1262-9
5. Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, et al. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer 2013;108:1052-60.
6. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14:933-42.
7. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, et al. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Can Res 2008; 68:521-9.